Literature DB >> 1031556

Anti-oestrogen therapy of advanced mammary carcinoma.

H Westerberg, B Nordenskjöld, A de Schryver, G Notter.   

Abstract

Forty mg daily of tamoxifen (Nolvadex) was administered orally to 89 patients with advanced soft tissue mammary carcinoma. At two months 43 per cent of the patients responded. At 6, 12 and 18 months, 42, 35 and 32 per cent, respectively, were still responding to therapy. The side effects were limited, fatique being the most frequent complaint. Oestrogen dependent side effects were not encountered. The therapeutic effect of tamoxifen is similar to that of oestrogen, but the side effects are less.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1031556     DOI: 10.3109/02841867609131975

Source DB:  PubMed          Journal:  Acta Radiol Ther Phys Biol        ISSN: 0567-8064


  5 in total

1.  On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer.

Authors:  E Petru; D Schmähl
Journal:  Klin Wochenschr       Date:  1987-10-15

Review 2.  A risk-benefit assessment of tamoxifen therapy.

Authors:  W H Catherino; V C Jordan
Journal:  Drug Saf       Date:  1993-05       Impact factor: 5.606

3.  The value of high dose tamoxifen in postmenopausal breast cancer patients progressing on standard doses: a pilot study.

Authors:  S M Watkins
Journal:  Br J Cancer       Date:  1988-03       Impact factor: 7.640

4.  A transgenic mouse model expressing an ERα folding biosensor reveals the effects of Bisphenol A on estrogen receptor signaling.

Authors:  Thillai V Sekar; Kira Foygel; Tarik F Massoud; Sanjiv S Gambhir; Ramasamy Paulmurugan
Journal:  Sci Rep       Date:  2016-10-10       Impact factor: 4.379

Review 5.  Current Medical Treatment of Patients with Non-Colorectal Liver Metastases: Primary Tumor Breast Cancer.

Authors:  Cornelia Liedtke; Hans-Christian Kolberg
Journal:  Viszeralmedizin       Date:  2015-12-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.